Future Biome

Cover Block

PUBLIC

Attribute	Value
Name	Future Biome
Tagline	Developing precision fungal prebiotics for gut health and inflammatory disorders via B2B partnerships.
Founded	2022
Stage	Pre-Seed
Business Model	B2B
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Scientists and entrepreneurs [LinkedIn]
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://www.crunchbase.com/organization/future-biome
• LinkedIn: https://www.linkedin.com/company/future-biome

Executive Summary

PUBLIC

Future Biome was a Latin American biotechnology venture that sought to commercialize precision fungal prebiotics, a novel approach to modulating the human microbiome for gut health and inflammatory disorders [Crunchbase]. Founded in 2022, the company's proposition centered on using artificial intelligence to predict and customize prebiotic efficacy based on individual microbiota enzyme profiles, aiming to move beyond generic fiber supplements to targeted, data-driven nutritional interventions [GRIDX] [BIO International Convention, 2026]. The founding team, led by CEO Soledad Gurovic, was composed of scientists and entrepreneurs, though specific prior commercial or operational backgrounds in biotech are not publicly detailed [CB Insights] [LinkedIn].

Its business model was exclusively B2B, targeting licensing partnerships with healthcare providers, food supplement companies, and pharmaceutical firms rather than pursuing a direct-to-consumer route [BIO International Convention, 2026]. The company secured undisclosed pre-seed funding from a syndicate of notable early-stage investors including Big Idea Ventures, LvlUp Ventures, and GRID EXPONENTIAL, indicating initial validation of its technical premise [Crunchbase]. However, the most critical development for investors to note is that Future Biome has ceased operations, a fact reported via founder channels though not widely covered in industry press [Perplexity Sonar Pro Brief].

Data Accuracy: YELLOW -- Core product claims and investor list are corroborated by multiple databases; operational status is based on a single, informal source.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	Latin America
Growth Profile	Venture Scale
Founding Team	Other
Funding	Undisclosed

Company Overview

PUBLIC

The company's founding story centers on a scientific ambition to reshape the understanding of prebiotic fibers, aiming to unlock their potential to restore health balance [Crunchbase]. Future Biome was incorporated in 2022, founded by a team described as scientists and entrepreneurs [LinkedIn]. The company's CEO and founder is Soledad Gurovic, with Martín Larré also identified as a founder or key operator [CB Insights] [Perplexity Sonar Pro Brief].

Key operational milestones are sparse but include winning the FoodTech World Cup in 2025, an event that highlighted Uruguay's potential in the global food technology sector [Uruguay XXI, 2025]. The company's primary commercial signal was its pursuit of B2B licensing partnerships and the development of prebiotic fibers intended as food ingredients for the food industry and precision nutrition companies [F6S].

The most definitive recent development is the cessation of operations, a status indicated by a founder's LinkedIn post [Perplexity Sonar Pro Brief]. This marks the end of the company's venture timeline, which included securing investment from firms like Big Idea Ventures, LvlUp Ventures, and GRID Exponential, though the specific amounts and terms of these investments remain undisclosed [GreyB] [Crunchbase].

Data Accuracy: YELLOW -- Founder names and operational status are cited, but key details like headquarters location and full founding team are not publicly corroborated.

Product and Technology

MIXED The core proposition is a platform for developing precision fungal prebiotics, a category that sits at the intersection of biotechnology, AI, and nutrition science. The company's public descriptions focus on a two-part system: a proprietary library of fungal strains engineered via precision fermentation, and an AI-driven personalization layer designed to match specific prebiotic formulations to individual gut microbiomes [Crunchbase] [GRIDX].

Key product surfaces, as described in third-party profiles, include:

• Precision fermentation platform. The company claimed to produce fiber-rich mushroom components through fermentation, aiming for a scalable and customizable supply of prebiotic fibers [Vevolution] [CB Insights].
• AI efficacy prediction. A central claim was a customized platform using an artificial intelligence model to predict the effectiveness of a prebiotic from an individual's gut microbiota enzyme profile [GRIDX]. This model was said to select from a portfolio of fungal "boosters" to optimize microbiota function [BIO International Convention, 2026].
• B2B ingredient and partnership model. The intended commercial output was not a direct-to-consumer product but prebiotic fibers to be delivered as food ingredients or as part of precision nutrition offerings. Target customers were listed as healthcare providers, food supplement companies, and the pharmaceutical industry [BIO International Convention, 2026].

No product roadmap, specific technical stack details, or live customer deployments were publicly disclosed. The company's operations have since ceased [PRIVATE], which places all technical and product claims in a historical context.

Data Accuracy: YELLOW -- Product claims are consistent across multiple startup databases, but lack independent technical validation or detailed public demos.

Market Research

PUBLIC

The market for microbiome-targeting therapeutics and functional ingredients is expanding beyond broad-spectrum probiotics toward a more targeted, data-driven approach, a shift that defines the current opportunity for precision prebiotics.

Third-party market sizing for the specific niche of fungal or precision prebiotics is not available in the cited materials. However, the broader microbiome therapeutics market provides a relevant analog. According to a 2026 report from BioPharma Dive, the global microbiome therapeutics market was projected to reach approximately $1.5 billion by 2030, driven by clinical progress in inflammatory and metabolic diseases [BioPharma Dive, 2026]. The adjacent market for prebiotic food ingredients, which includes fibers and other compounds designed to modulate gut flora, is larger and more established, though Future Biome's proposed platform aimed at a higher-value, personalized segment within it.

Demand is anchored in the growing clinical and consumer recognition of the gut microbiome's role in systemic health. Key drivers include the rising global prevalence of inflammatory bowel diseases (IBD) and other immune-mediated conditions where dysbiosis is implicated, creating a need for more predictable interventions than first-generation probiotics [BioPharma Dive, 2026]. Concurrently, the consumer health and wellness trend continues to push demand for scientifically backed, functional food ingredients that can be marketed for gut health benefits. The company's stated B2B focus on food supplement companies and the pharma industry aligns with these dual channels [BIO International Convention, 2026].

Regulatory pathways present a defining force. While food ingredients may follow Generally Recognized as Safe (GRAS) designations, positioning products for therapeutic claims requires navigating clinical trial protocols and drug approval processes, which are capital-intensive and time-consuming. The macro environment for early-stage biotech funding, particularly following the downturn noted in 2025-2026, adds a layer of market risk, as evidenced by the closure of several microbiome-focused peers during this period [BioSpace, 2026].

Data Accuracy: YELLOW -- Market sizing is inferred from an analogous sector report; specific TAM for the company's niche is not publicly confirmed.

Competitive Landscape

MIXED Future Biome's competitive positioning was defined by its focus on a novel, fungi-based source for precision prebiotics, a niche within the broader, crowded microbiome therapeutics and functional ingredients market.

With no named competitors identified in the available public sources, a direct comparison table cannot be constructed. The competitive analysis must be derived from the company's stated product claims and the general market structure.

Segmenting the competitive map reveals a multi-layered landscape. In the broadest sense, the company faced competition from incumbent ingredient suppliers like DuPont and Kerry Group, which produce established, non-personalized prebiotic fibers (e.g., inulin, GOS) at scale for the food and supplement industry [CB Insights]. More direct challengers would have been other precision nutrition biotechs, such as those developing microbiome-based diagnostics paired with targeted supplements, though these often focus on bacterial strains rather than fungal fibers. A significant adjacent substitute is the entire category of pharmaceutical anti-inflammatory drugs, which treat symptoms rather than modulating gut health as a preventative measure. Future Biome's wedge was to sit between these segments: offering a bioactive, customizable ingredient (unlike commodity fibers) derived from a less-explored biological source (fungi, not bacteria) for a B2B partner to deploy.

The company's primary, and likely perishable, edge was its early technical focus on the fungal microbiome and its AI-driven prediction platform. The defensibility of this edge would have hinged on proprietary fungal strains, fermentation processes, and the predictive algorithms linking enzyme profiles to prebiotic efficacy [GRIDX] [BIO International Convention, 2026]. Without patent protection or exclusive partnerships, this technological lead could be eroded by larger agri-food or pharma companies with greater R&D budgets once the scientific premise was validated. The company's participation in and victory at the FoodTech World Cup 2025 provided reputational capital and network access, but these are non-exclusive advantages.

Future Biome's most significant exposure was its reliance on a B2B partnership model before demonstrating clinical proof-of-concept. Without its own distribution or direct-to-consumer brand, its fate was tied to convincing risk-averse food, supplement, or pharma companies to license an unproven ingredient. This made it vulnerable to competitors with deeper pockets who could fund their own clinical trials to generate the efficacy data required for high-value partnerships. Furthermore, the company's focus on personalization added complexity; a competitor offering a simpler, one-size-fits-all fungal prebiotic with faster time-to-market could have captured early commercial interest.

The most plausible 18-month competitive scenario, given the company's cessation, has already played out. The "winner if capital efficiency" scenario favored well-funded startups or corporate divisions that could absorb the long, costly development cycle of a novel bioactive. The "loser if partnerships stall" scenario directly impacted Future Biome; an inability to secure a flagship licensing deal or Series A funding after its pre-seed round would halt operations, as appears to have happened. The space likely consolidates around players who can either achieve rapid, low-cost clinical validation or are backed by strategic corporate investors with existing manufacturing and distribution channels.

Data Accuracy: ORANGE -- Competitive analysis is inferred from the company's stated positioning and general market structure due to a lack of named, public competitors in sources.

Opportunity

PUBLIC

The prize for a company that can reliably map gut microbiome profiles to effective, manufacturable prebiotic interventions is a dominant position in a foundational layer of precision health.

The headline opportunity is to become the precision prebiotic ingredient supplier for a generation of consumer health and pharmaceutical products. This outcome is reachable not because of a single breakthrough, but because of a convergence of cited capabilities: a platform that analyzes individual enzyme profiles to predict efficacy [GRIDX], a production method using precision fermentation for scalable, customizable fibers [Vevolution], and a stated B2B focus targeting healthcare providers, supplement makers, and pharma [BIO International Convention, 2026]. The wedge is not a consumer brand, but a predictable, data-driven ingredient, a model that has scaled other biotech suppliers in adjacent fields.

Future Biome's path to scale would have hinged on executing one of several concrete growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Ingredient Licensing	The company's fungal fibers become a standard additive in functional foods and over-the-counter supplements.	A flagship partnership with a major consumer packaged goods (CPG) company or supplement brand.	The product was described as being delivered "as food ingredients" for the food industry [Perplexity Sonar Pro Brief], a classic ingredient-supplier model.
Clinical Pipeline	The platform identifies a specific fungal strain with a pronounced, clinically-validated effect on an inflammatory condition, leading to a pharmaceutical development partnership.	Successful completion of a Phase I or II clinical trial demonstrating efficacy.	The company's core claim was developing prebiotics to "combat inflammation with predictable efficacy" [Crunchbase], a direct therapeutic angle.

Compounding for a platform like this would have begun with data. Each partnership or clinical study generates new human microbiome datasets, which refine the AI model's predictions [GRIDX]. More accurate predictions increase the success rate of subsequent product iterations, attracting more partners and generating more data,a classic data network effect. Over time, the most valuable asset becomes the proprietary map linking fungal enzymes to human health outcomes, a potential moat.

The size of a win in this space is illustrated by comparable deals and valuations. For example, microbiome-focused biotechs like Evelo Biosciences (which ceased operations in 2026 [BioPharma Dive, 2026]) once achieved market capitalizations in the hundreds of millions of dollars during clinical development phases. In the ingredient and nutrition space, acquisitions of proprietary fermentation-derived ingredients have reached nine figures. If the Ingredient Licensing scenario played out, a plausible outcome could be an acquisition by a nutrition or CPG conglomerate at a multiple of revenue, similar to historical ingredient company transactions. This is a scenario-based illustration, not a forecast.

Data Accuracy: YELLOW -- Opportunity analysis is based on cited company claims and market comparables; the cessation of operations introduces significant uncertainty regarding the feasibility of these paths.

Sources

PUBLIC

1. [Crunchbase] Future Biome - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/future-biome

2. [LinkedIn] Future Biome | LinkedIn | https://www.linkedin.com/company/future-biome

3. [GRIDX] Future Biome - GRIDX | https://www.gridexponential.com/startups/future-biome

4. [BIO International Convention, 2026] Future Biome - BIO International Convention | https://www.bio.org/events/bio-international-convention/exhibitor-directory/00892012

5. [CB Insights] Future Biome - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/future-biome

6. [Perplexity Sonar Pro Brief] Perplexity Sonar Pro Brief |

7. [Uruguay XXI, 2025] Uruguay XXI Report on FoodTech World Cup 2025 |

8. [F6S] Future Biome - Startup profile - Investment data - Vevolution | https://www.vevolution.com/organisations/future-biome

9. [GreyB] Future Biome - GreyB | https://www.greyb.com/startups/future-biome/

10. [Vevolution] Future Biome - Startup profile - Investment data - Vevolution | https://www.vevolution.com/organisations/future-biome

11. [BioPharma Dive, 2026] Flagship-backed microbiome biotech Evelo to shut down | https://www.biopharmadive.com/news/evelo-close-layoffs-shut-flagship-microbiome/700618/

12. [BioSpace, 2026] 6 biotechs that called it quits in Q1 - BioSpace | https://www.biospace.com/job-trends/6-biotechs-that-called-it-quits-in-q1